Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Evidence suggesting that central nervous system γ-aminobutyric acid (GABA) concentrations are reduced in patients with major depressive disorder (MDD) has been present since at least 1980, and this idea has recently gained support from more recent magnetic resonance spectroscopy data. These observations have led to the assumption that MDD's underlying etiology is tied to an overall reduction in GABA-mediated inhibitory neurotransmission. In this paper, we review the mechanisms that govern GABA and glutamate concentrations in the brain, and provide a comprehensive and critical evaluation of the clinical data supporting reduced GABA neurotransmission in MDD. This review includes an evaluation of magnetic resonance spectroscopy data, as well as data on the expression and function of the GABA-synthesizing enzyme glutamic acid decarboxylase, GABA neuron-specific cell markers, such as parvalbumin, calretinin and calbindin, and the GABAA and GABAB receptors in clinical MDD populations. We explore a potential role for glial pathology in MDD-related reductions in GABA concentrations, and evidence of a connection between neurosteroids, GABA neurotransmission, and hormone-related mood disorders. Additionally, we investigate the effects of GABAergic pharmacological agents on mood, and demonstrate that these compounds have complex effects that do not universally support the idea that reduced GABA neurotransmission is at the root of MDD. Finally, we discuss the connections between serotonergic and GABAergic neurotransmission, and show that two serotonin-focused antidepressants - the selective serotonin-reuptake inhibitor fluoxetine and the multimodal antidepressant vortioxetine - modulate GABA neurotransmission in opposing ways, despite both being effective MDD treatments. Altogether, this review demonstrates that there are large gaps in our understanding of the relationship between GABA physiology and MDD, which must be remedied with more data from well-controlled empirical studies. In conclusion, this review suggests that the simplistic notion that MDD is caused by reduced GABA neurotransmission must be discarded in favor of a more nuanced and complex model of the role of inhibitory neurotransmission in MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225 · cited 1×
“66 Acute allopregnanolone administration also has well-recognized behavioral effects that are consistent with a positive modulatory effect on GABA neurotransmission, including anxiolytic 67 and seizure-reducing 68 properties.”
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477 · cited 1×
“These observations include reductions in size and density of glia, 46 as well as reductions in the gene or protein expression of glial-specific markers, such as glial fibrillary acidic protein, the calcium-binding protein S100B, EAAT1, EAAT2, and glutamine synthetase.”
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 2×
“21 It is possible that reductions in OCC GABA concentrations are specific to a subpopulation of treatment-resistant patients, as at least one study has shown that treatment-resistant, but not non-treatment-resistant, MDD patients have reduced OCC GABA concentrations.”
Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380401 · Cited by 765
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Sanacora, G., Mason, G. F., Rothman, D. L., Behar, K. L., Hyder, F., Petroff, O. A. C., Berman, R. M., Charney, D. S., & Krystal, J. H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.1043 · Cited by 627
Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Rajkowska, G., & Stockmeier, C. (2013) · Current Drug Targets · doi:10.2174/13894501113149990156 · Cited by 603 · cited 2×
“47,48 These glial pathologies can be theoretically important for a discussion of GABA neurotransmission from the perspective that glial cells, such as astrocytes, regulate glutamate–glutamine cycling through cellular machinery that includes EAAT1/2 and glutamine synthetase (see earlier discussion…”
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“81 We have identified a small number of studies to date that have measured changes in neurosteroid levels in MDD patients in response to treatment with antidepressants.”
Neurocognitive deficits and disability in major depressive disorder
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.011 · Cited by 484
Cited by
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
GABAA receptors: structure, function, pharmacology, and related disorders
Ghit, A., Assal, D., Al-Shami, A. S., & Hussein, D. E. E. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00224-0 · Cited by 405
Zhu, H., Bi, D., Zhang, Y., Kong, C., Du, J., Wu, X., Wei, Q., & Qin, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00831-w · Cited by 399
An astroglial basis of major depressive disorder? An overview
Wang, Q., Jie, W., Liu, J., Yang, J., & Gao, T. (2017) · Glia · doi:10.1002/glia.23143 · Cited by 222
Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression
Trzeciak, P., & Herbet, M. (2021) · Nutrients · doi:10.3390/nu13030927 · Cited by 139
“Lowered GABA levels in the nervous system have been shown in depressed patients in comparison to healthy controls [23].”
Metadata
- Authors
- Pehrson, A., & Sanchez, C.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-01
- Volume
- 9
- Pages
- 603
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1977856078
- Cited by
- 145
- References
- 29
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. https://app.cochat.ai/papers/10.2147/dddt.s62912
- The paper
- Pehrson, A., & Sanchez, C. (2015). Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s62912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.